← back to search

Susan J. Ramus

Cancer Institute of New South Wales ·
Area of research
Reproductive Medicine · Genetics
Research interest
Research interests include Ovarian cancer diagnosis and treatment, BRCA gene mutations in cancer, Cancer-related molecular mechanisms research, and PARP inhibition in cancer therapy.
h-index
78
citations
23,587
works
749
NIH funding
primary concept
email

Recent publications

Cellular origins of mucinous ovarian carcinoma
The Journal of Pathology 2025cited by 12position: middledoi
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis
Gynecologic Oncology 2025cited by 2position: middledoi
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer
European Journal of Human Genetics 2025cited by 1position: middledoi
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Journal of Clinical Investigation 2024cited by 17position: middledoi
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Clinical Cancer Research 2024cited by 12position: middledoi
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
JNCI Journal of the National Cancer Institute 2023cited by 25position: middledoi
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer 2023cited by 17position: middledoi
Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility
JAMA Network Open 2023cited by 11position: middledoi
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Clinical Cancer Research 2023cited by 10position: middledoi
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
medRxiv 2023cited by 5position: middledoi
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Nature Genetics 2022cited by 109position: middledoi
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia
Journal of Clinical Oncology 2022cited by 30position: middledoi
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology 2022cited by 26position: lastdoi
Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors
Journal of Medical Genetics 2021cited by 58position: middledoi
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
The Journal of Pathology 2021cited by 41position: middledoi
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer
Human Genetics and Genomics Advances 2021cited by 17position: middledoi
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
medRxiv 2021cited by 4position: middledoi
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.
Apollo (University of Cambridge) 2021cited by 0position: middledoi
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i>
JNCI Journal of the National Cancer Institute 2020cited by 161position: middledoi
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
British Journal of Cancer 2020cited by 68position: middledoi
Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer
Journal of Medical Genetics 2020cited by 58position: middledoi
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
JNCI Journal of the National Cancer Institute 2020cited by 37position: middledoi
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Gynecologic Oncology 2020cited by 28position: middledoi
Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 7position: middledoi
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies new candidate susceptibility genes for breast and ovarian cancer
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 6position: middledoi
Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case–control studies
European Journal of Epidemiology 2020cited by 1position: middledoi
Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families
Journal of Clinical Oncology 2019cited by 409position: middledoi
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Modern Pathology 2019cited by 98position: middledoi
Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity
Clinical Cancer Research 2019cited by 75position: middledoi
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Nature reviews. Cancer 2019cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul D.P. Pharoah · University of Thessaly8 papers (2017–2025)Simon A. Gayther · MRC Clinical Trials Unit at UCL7 papers (2012–2025)Usha Menon · Amrita Institute of Medical Sciences and Research Centre5 papers (2017–2023)Ellen L. Goode · Mayo Clinic5 papers (2012–2019)Andrew Berchuck · Duke University5 papers (2017–2025)Marc T. Goodman · Cancer Institute of New South Wales4 papers (2012–2023)Kirsten B. Moysich · Dartmouth College3 papers (2018–2023)Joellen M. Schildkraut · Institute of Biomedical Sciences, Academia Sinica3 papers (2017–2023)Francesmary Modugno · University of Pittsburgh3 papers (2018–2023)Martin Köbel · University of Calgary3 papers (2016–2025)Celeste Leigh Pearce · University of Michigan3 papers (2019–2023)Ian Jacobs · Children's Hospital of Philadelphia3 papers (2017–2021)Penelope M. Webb · QIMR Berghofer Medical Research Institute3 papers (2020–2025)David D.L. Bowtell · Peter MacCallum Cancer Centre3 papers (2018–2019)Ranjit Manchanda · All India Institute of Medical Sciences Bhubaneswar3 papers (2017–2021)Antonis C. Antoniou · University of Cambridge3 papers (2017–2021)Aleksandra Gentry‐Maharaj · Respiratory Clinical Trials3 papers (2018–2021)Nicolas Wentzensen · National Cancer Institute2 papers (2019–2023)Xin Yang · Sun Yat-sen University2 papers (2018–2021)Anna H. Wu · University of Southern California2 papers (2020–2023)